共查询到20条相似文献,搜索用时 15 毫秒
1.
Raquel P. Souza André L. P. de Abreu érika C. Ferreira Sheila C. Rocha-Brischiliari Maria D. de B. Carvalho Sandra M. Pelloso Marcelo G. Bonini Fabrícia Gimenes Marcia E. L. Consolaro 《The American journal of tropical medicine and hygiene》2013,89(6):1199-1202
We determined the prevalence of seven clinically important pathogens that cause sexually transmitted infections (STIs) (Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium, Trichomonas vaginalis, herpes simplex virus 1 [HSV-1], HSV-2, and Treponema pallidum), by using a multiplex polymerase chain reaction (M-PCR) in samples from Brazilian woman infected with human immunodeficiency virus 1 (HIV-1) and uninfected Brazilian women (controls). The M-PCR assay identified all STIs tested for and surprisingly, occurred association between the control and STIs. This association was probably caused by excellent HIV infection control and regular monitoring in these women established by public health strategies in Brazil to combat HIV/acquired immunodeficiency syndrome. Studies using this M-PCR in different populations may help to better elucidate the roles of STIs in several conditions.It is estimated that annually more than 340 million new cases of sexually transmitted infections (STIs) occur throughout the world, and the highest incidence is in developing countries. Pelvic inflammatory disease, infertility, ectopic pregnancy, chronic pelvic pain, neonatal morbidity and mortality, and genital cancer all have been assumed to be associated with STIs, although in many cases the exact etiologic agents remain unknown.1 Furthermore, an increasing risk of acquisition of these infections may have a substantial impact on global human immunodeficiency virus 1 (HIV-1) transmission and have the potential to cause serious health risks in HIV-infected persons.2–4 However, few studies in Latin America have examined the reciprocal effect of HIV-1 on susceptibility and prevalence to STIs.Over the past three decades, diagnostics for STIs depended on traditional methods such as culture, enzyme immunoassay, and fluorescent antibody staining. However, in recent years several molecular methods have become available. These newer methods have advantages because they are more sensitive, enabling detection in symptomatic and asymptomatic patients, including cases of viral infections.5 The multiplex PCR has an additional advantage in screening because it enables simultaneous detection of multiple pathogens, reducing costs and time.6The purpose of this study was to determine the prevalence of seven clinically important STIs: Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium, Trichomonas vaginalis, herpes simplex virus 1 (HSV-1), HSV-2, and Treponema pallidum by using multiplex PCR (M-PCR) in samples from HIV-1-infected Brazilian women and those from HIV1-uninfected Brazilian women.A total of 556 women were randomly selected for this study: 178 HIV-infected (HIV group) and 378 HIV-uninfected women (control group) registered in the Public Specialized Assistance Service for HIV/acquired immunodeficiency syndrome (AIDS) for detection and control in Maringá/Paraná, Brazil, during April 2011–May 2012. Women spontaneously sought testing for HIV detection. Inclusion criteria were HIV-infected or uninfected women independent of signs and symptoms for STIs determined by a gynecologist; and HIV-infected or uninfected women who had two negative or positive diagnoses for HIV/AIDS by different methods, respectively. Exclusion criteria were pregnancy, age < 18 years, and no history of sexual activity. Data regarding HIV infection and treatment were obtained from Public Specialized Assistance Service medical records. This study was approved by the Committee for Ethics in Research Involving Humans at the State University of Maringá, Paraná, Brazil (no. 085/2011), and each woman involved signed a consent form.Cervical, endocervical and vaginal samples were collected by using a cytobrush and an Ayre''s spatula, transferred to tubes containing 1.0 mL of sterile 0.9% NaCl solution, and stored at −20°C. DNA was extracted by using an AxyPrep™ Body Fluid Viral DNA/RNA Miniprep Kit (Axygen, Union City, CA) according to the manufacturer''s instructions. The quality and quantity of purified DNA were measured by spectrophotometry.We made selected adaptations to a previously designed M-PCR to achieve simultaneous detection of the seven selected STIs.5,6 Primers were characterized by compatible melting temperatures and yielded amplicons with sizes easily separable by agarose gel electrophoresis (7 All clinical samples were also tested by using specific primers GH20/ PC04 for the human β-globin gene as an internal control of amplification and DNA integrity under the same conditions of M-PCR or single-target PCR.
Open in a separate window*HSV = herpes simplex virus.Statistical analysis was performed by using STATISTICA 8.0 software (StatSoft Inc., Tulsa, OK), and all variables were expressed as absolute and relative frequencies. The prevalence rates of STIs in women groups were compared by using a non-parametric Z test. A P value < 0.05 was considered statistically significant.The median ± SD age of the HIV group was 41.2 ± 10.3 years, which was similar to that of the control group (42.05 ? 13.05 years). Most of the HIV group had been infected by this virus between 2 to 10 years (62.9%), and showed excellent HIV control by: using highly active antiretroviral therapy (HAART) correctly (79.1%), having CD4 > 350 cell/mm3 (73.6%) and a viral load from < minimal limits to 100.000 copies/mL (97.1%).The M-PCR clearly distinguished and correctly identified all seven STIs, whether alone (1 STI) or simultaneously (2–3 STIs), and false-positives results were not detected. Final results, after repeating any tests that showed discrepant results, were accepted as true positives if the single-target PCR result was positive. The overall agreement of M-PCR results with single-target PCR results was 98.82% and the validation parameters were as follows: sensitivity 95.75%, specificity and positive predictive value 100% for both, negative predictive value 98.94% and accuracy 99.4%. Trichomonas vaginalis, HSV-1, C. trachomatis, and T. pallidum showed values of 100% for all parameters. The same results were observed for cases of simultaneous detection of 2 or 3 STIs (Figure 1.Open in a separate windowFigure 1.Electrophoretic analysis of the amplified fragments by using a multiplex polymerase chain reaction on an 8% polyacrylamide gel stained with ethidium bromide. Lane C1: control of Mycoplasma genitalium, Trichomonas vaginalis and herpes simplex virus 1 (HSV-1) (193, 170, and 123 bp) triple infection; lane C2: control of HSV-2 and T. vaginalis (249 and 170 bp) double infection; lane C3: control of Chlamydia trachomatis (361 bp); lane C4: control of Treponema pallidum and HSV-2 (291 and 249 bp) double infection; lane C5: control of Neisseria gonorrhoeae (162 bp); lane A1: positive sample of C. trachomatis (361 bp); lane A2: positive sample of T. vaginalis (170 bp); lane A3: positive sample of HSV-2 (249 bp); lane A4: positive sample of T. pallidum (291 bp); lane A5: positive sample of HSV-1 (123 bp); lane A6: positive sample of N. gonorrhoeae (162 bp); lane A7: positive sample of T. vaginalis (170 bp); lane A8: positive sample of M. genitalium and T. vaginalis (193 and 170 bp) double infection; lanes M, molecular mass marker (25 and 100 bp). Values on the left and right sides of the gel are in bp.
Open in a separate window*PCR = polymerase chain reaction; STIs = sexually transmitted infections; PPV = positive predictive value; NPV = negative predictive value.The control group showed a higher prevalence of STIs (n = 152, 66.1% of STIs detected) than the HIV group (n = 78) (P = 0.0001). However, there was no difference in the prevalence of each STI between both groups (Agent Total STDs detected, no. (%)† STDs in HIV group, no. (%)† STDs in control group, no. (%)† P Trichomonas vaginalis 69 (30.0) 20 (25.7) 49 (32.2) 0.6067 Chlamydia trachomatis 62 (26.9) 18 (23.1) 44 (28.9) 0.0562 HSV-2 25 (10.9) 15 (19.2) 10 (6.6) 0.3852 Neisseria gonorrhoeae 25 (10.9) 6 (7.7) 19 (12.5) 0.7495 Mycoplasma genitalium 25 (10.9) 8 (10.2) 17 (11.2) 0.9290 Treponema pallidum 16 (6.9) 8 (10.3) 8 (5.3) 0.7148 HSV-1 8 (3.5) 3 (3.8) 5 (3.3) 0.9714 Total 230 (100.0) 78 (33.9) 152 (66.1) 0.0001‡
Table 1
Nucleotide sequences of amplification primers used in the multiplex polymerase chain reaction*Organism and primer | Primer sequence (5′→3′) | Amplicon size (base pairs) |
---|---|---|
Chlamydia trachomatis | ||
Forward | TCTTTTTAAACCTCCGGAACCCACTT | 361 |
Reverse | GGATGGCATCGCATAGCATTCTTTG | 361 |
Neisseria gonorrhoeae | ||
Forward | CGGCAGCATTCAATTTGTTAAAAAGC | 162 |
Reverse | CGCCATTTTTGTA | 162 |
Mycoplasma genitalium | ||
Forward | ACCTTGATGGTCAGCAAAACTTCCTT | 193 |
Reverse | TGATCTCATTCCAATCAGTA | 193 |
Trichomonas vaginalis | ||
Forward | CCAGAAGTGGGCTACACACCATACC | 170 |
Reverse | AAGGCCGGAAGCAC | 170 |
HSV-1 | ||
Forward | CTGTGGTGTTTTTGGCATCAGGTTGT | 123 |
Reverse | GGAGGAGACGTTG | 123 |
HSV-2 | ||
Forward | CATGGGGCGTTTGACCTCTACACAGT | 249 |
Reverse | GATCGGGATGCT | 249 |
Treponema pallidum | ||
Forward | GGAGAAGTTTCACTTCGTGGACTCGC | 291 |
Reverse | GTCATCACCGTAGTA | 291 |
Table 2
Multiplex PCR validation results compared with single PCR for seven pathogens causing clinically important STIs*Multiplex PCR validation parameters | General results (%) | Chlamydia trachomatis (%) | Neisseria gonorrhoeae (%) | Mycoplasma genitalium (%) | Trichomonas vaginalis (%) | HSV-1 (%) | HSV-2 (%) | Treponema pallidum (%) | Two or three STIs simultaneously (%) |
---|---|---|---|---|---|---|---|---|---|
Sensitivity | 95.75 | 100.00 | 91.66 | 87.50 | 100.00 | 100.00 | 90.91 | 100.00 | 100.00 |
Specificity | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100 | 100.00 | 100.00 |
PPV | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100 | 100.00 | 100.00 |
NPV | 98.94 | 100.00 | 97.43 | 97.67 | 100.00 | 100.00 | 97.5 | 100.00 | 100.00 |
Accuracy | 99.40 | 100.00 | 100.00 | 98.00 | 100.00 | 100.00 | 98.00 | 100.00 | 100.00 |
Agreement | 98.82 | 100.00 | 89.90 | 88.57 | 100.00 | 100.00 | 90.91 | 100.00 | 100.00 |